Data ụlọ ọgwụ ọhụrụ dị mma na ndị ọrịa nwere ọrịa kansa eriri afọ

Mirati Therapeutics, Inc., ụlọ ọrụ oncology ezubere iche maka ụlọ ọgwụ, taa kwupụtara nsonaazụ dị mma sitere na ngalaba nke abụọ nke ọmụmụ KRYSTAL-2 na-enyocha adagrasib na 1mg BID dose na ndị ọrịa nwere adenocarcinoma ductal pancreatic pretreated na etuto afọ afọ (GI). na-ejide ngbanwe nke KRASG600C, gụnyere ọrịa cancer nke traktị biliary, appendix, obere bowel, gastro-esophageal junction, na esophagus. Nsonaazụ gosiri na adagrasib gosipụtara nnukwu ọrụ ụlọ ọgwụ yana njikwa ọrịa sara mbara.

Print Friendly, PDF & Email

A ga-ewepụta nchoputa (Abstract # 519) taa na 10:00 am ET n'oge nnọkọ ngwa ngwa na 2022 American Society for Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium.      

Dr. Tanios S. Bekaii-Saab, onye nyocha nke nyocha nke KRYSTAL-1, kwuru, sị, "ọrịa cancer nke eriri afọ bụ ụfọdụ n'ime ọrịa cancer na-emekarị ma nọgide na-ejikọta ya na nsonaazụ ndụ na-adịghị mma n'agbanyeghị ọganihu ndị na-adịbeghị anya, karịsịa na ndị ọrịa nwere ọrịa GI na-ebute. Mmụba nke KRASG12C. Data ụlọ ọgwụ ọhụrụ ewepụtara na ASCO GI na-egosi na adagrasib, onye na-egbochi KRASG12C, gosipụtara ọrụ ụlọ ọgwụ na-ekwe nkwa na ndị ọrịa nwere ọrịa kansa pancreatic na etuto GI ndị ọzọ. Nchọpụta ndị a na-adabere na data ahụike adagrasib nke akọwara na mbụ na ọrịa cancer colorectal na pancreatic, ma na-agba ume nke ukwuu, na-enye ohere nyocha ọzọ nke adagrasib na ọnọdụ a. "

Nchịkọta nke nsonaazụ ụlọ ọgwụ

• Dị ka nke Septemba 10, 2021, akụkụ nke ndị ọrịa nwere ọrịa cancer GI na-ebu mmụgharị KRASG12C debanyere aha na ogwe aka adagrasib monotherapy (n=30) natara opekata mpe ahịrị abụọ tupu usoro ọgwụgwọ anticancer, ma nwee usoro nleba anya nke ọnwa 6.3. .

• N'ime ndị ọrịa a na-enyocha (n=27), ọnụego nzaghachi ebumnobi (ORR) bụ 41% yana ọnụ ọgụgụ nchịkwa ọrịa (DCR) bụ 100%. N'ime ndị ọrịa nwere ọrịa cancer pancreatic (n = 10), ọnụego nzaghachi (RR) bụ 50%, gụnyere 1 nzaghachi akụkụ nke na-akwadoghị (PR); Ogologo oge nzaghachi nke etiti (mDOR) bụ ọnwa 7.0, yana nsochi etiti ọnwa 8.1. N'ime ndị ọrịa nwere etuto GI ndị ọzọ (n = 17), RR bụ 35%, yana PR abụọ na-akwadoghị; mDOR bụ ọnwa 7.9 n'ime ndị ọrịa a, yana nsochi etiti ọnwa 6.3.

• Ọganihu na-aga n'ihu n'efu (mPFS) na ndị ọrịa nwere ọrịa cancer pancreatic bụ ọnwa 6.6 (95% Interval Confidence Interval, CI: 1.0, 9.7), na ndị ọrịa nwere etuto GI ndị ọzọ, mPFS bụ ọnwa 7.9 (95% CI 6.90- 11.30).

• Na mkpokọta nke ndị ọrịa nwere ọrịa cancer KRASG12C-mutated GI tụlere na otu a, adagrasib nabatara nke ọma, yana profaịlụ nchekwa nwere ike ijikwa. A na-ahụ ọkwa 3 / 4 omume ọjọọ metụtara ọgwụgwọ (TRAEs) na 27% nke ndị ọrịa na-emeso adagrasib, na-enweghị TRAE nke na-eduga n'ịkwụsị ọgwụgwọ, ọ dịghịkwa ọkwa 5 TRAE.

"Anyị kwenyere na adagrasib nwere profaịlụ dị iche iche nke mkpụrụ ndụ ihe nketa, na data ndị a na-enye na ASCO GI na-akwadokwa profaịlụ ya kachasị mma," ka Charles M. Baum, MD, Ph.D., onye nchoputa, onyeisi oche na onye isi nyocha na kwuru. mmepe, Mirati Therapeutics, Inc. "Nsonaazụ gosipụtara ọrụ nlekọta ahụike dị mma na ndị ọrịa nwere KRASG12C-mutated GI cancers na-emeso ya na adagrasib otu onye ọrụ, karịsịa na ndị nwere ọrịa cancer pancreatic ebe nhọrọ dị oke. Anyị na-aga n'ihu na-enyocha adagrasib dị ka otu onye na-ejikọta ya na ọgwụ ọrịa cancer ndị ọzọ na atụmatụ mmepe sara mbara iji nyere ọtụtụ ndị nwere ọrịa cancer aka. "

Print Friendly, PDF & Email

Akụkọ ndi ozo

Banyere chepụtara

nchịkọta akụkọ

Onye nchịkọta akụkọ nke eTurboNew bụ Linda Hohnholz. Ọ dabere na eTN HQ na Honolulu, Hawaii.

Ahapụ a Comment